NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has completed a collaboration with MLL Munich Leukemia Laboratory on the development of a panel for use in the sequence-based analysis of acute myeloid leukemia and myelodysplastic syndromes.
According to the partners, the panel will be used at MLL and will be made commercially available to RainDance's customers worldwide. The panel will enable researchers to analyze more than 25 genes at the single base level, they said. In addition, it contains more than 1,300 amplicons and is based on RainDance's DirectSeq tailed library strategy, providing coverage of over 235Kb of gene sequence simultaneously for downstream analysis on next-generation sequencing systems.
"We are pleased to be collaborating with MLL and believe that the AML/MDS content panel we've developed together will enable translational researchers to better characterize life-threatening cancers," RainDance President and CEO Roopom Banerjee said in a statement.
In addition to the collaborative efforts on the panel, Lexington, Mass.-based RainDance said that MLL has purchased its ThunderStorm System and consumables to process an initial 2,000 samples for use in identifying prognostically relevant molecular mutations associated with AML and other myeloid malignancies. The ThunderStorm System is a high-throughput platform for target sequence enrichment that uses RainDance's microdroplet-based PCR technology.